Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Income: 2022-2025

Historic Operating Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$53.8 million.

  • Centessa Pharmaceuticals' Operating Income fell 15.91% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 32.26%. This contributed to the annual value of -$201.1 million for FY2024, which is 17.38% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Operating Income stood at -$53.8 million, which was up 1.58% from -$54.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Operating Income ranged from a high of -$30.8 million in Q1 2025 and a low of -$74.6 million during Q4 2024.
  • Moreover, its 3-year median value for Operating Income was -$46.4 million (2024), whereas its average is -$46.5 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Operating Income surged by 31.27% in 2023 and then crashed by 112.01% in 2024.
  • Centessa Pharmaceuticals' Operating Income (Quarterly) stood at -$41.6 million in 2022, then increased by 15.44% to -$35.2 million in 2023, then plummeted by 112.01% to -$74.6 million in 2024, then fell by 15.91% to -$53.8 million in 2025.
  • Its Operating Income stands at -$53.8 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$30.8 million for Q1 2025.